Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma(2022 edition)  

作　　者：Juxian Sun Qiu Li Xueli Bai Jianqiang Cai Yajin Chen Minshan Chen Chaoliu Dai Chihua Fang Weidong Jia Xiangcheng Li Tianfu Wen Jinglin Xia Mingang Ying Zhiwei Zhang Xuewen Zhang Zhaochong Zeng Shuqun Cheng On behalf of Chinese Association of Liver Cancer and Chinese Medical Doctor Association 

机构地区：[1]Department of Hepatic Surgery VI,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,China [2]Department of Medical Oncology,Cancer Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [3]Department of Hepatobiliary and Pancreatic Surgery,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310003,China [4]Department of Hepatobiliary Surgery,Cancer Hospital,Chinese Academy of Medical Sciences,Beijing 100021,China [5]Department of Hepatobiliopancreatic Surgery,Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University,Guangzhou,Guangdong 510120,China [6]Department of Hepatobiliary Surgery,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong 510050,China [7]Department of Hepatobiliary and Spleenary Surgery,The Affiliated Shengjing Hospital,China Medical University,Shenyang,Liaoning 110022,China [8]Department of Hepatobiliary Surgery,Zhujiang Hospital,First Military Medical University,Guangzhou,Guangdong 510280,China [9]Department of General Surgery,Anhui Key Laboratory of Hepatopancreatobiliary Surgery,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,University of Science and Technology of China,Hefei,Anhui 230031,China [10]Hepatobiliary Center,The First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Living Donor Liver Transplantation,Nanjing,Jiangsu 210029,China [11]Department of Liver Surgery,West China Hospital of Sichuan University,Chengdu,Sichuan 610041,China [12]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang 325000,China [13]Liver Cancer Institute&Zhongshan Hospital,Fudan University,Shanghai 200030,China [14]Department of Gastrointestinal Oncological Surgery,Fujian Provincial Cancer Hospital,Fujian Medical University Teaching Hospital,Fuzhou,Fujian 350014,China [15]Department of Surgery,Hepatic Surgery Center,Institute of HBP Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China [16]Department of H

出　　处：《Chinese Medical Journal》2024年第21期2630-2632,共3页中华医学杂志(英文版)

基　　金：supported by grants from the State Key Project of the National Natural Science Foundation of China(No.81730097);the Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center(Joint Project of Emerging Frontier Technology)(No.SHDC12018116);the Clinical Research Plan of Shanghai Hospital Development Center(No.SHDC2020CR1004A).

摘　　要：To the Editor:Primary liver cancer is one of the most common malignant tumors in China.In 2020,410,038 new cases of liver cancer and 391,152 deaths due to liver cancer were reported in China,which places liver cancer as the second most common cancer-related cause of death in China;of these cancers,hepatocellular carcinoma(HCC)accounts for 85-90%.[1]HCC poses a significant threat to the lives and health of Chinese people.

关 键 词：HEPATOCELLULAR DRUGS cancer 

分 类 号：R73[医药卫生—肿瘤]